Immune-mediated Modulation of Breast Cancer Growth and Metastasis by the Chemokine Mig (CXCL9) in a Murine Model

Current immunotherapies are limited by several factors, including the failure to recruit sufficient numbers of immune effector cells to tumors. The chemokine monokine induced by γ-interferon (Mig; CXCL9) attracts activated T cells and natural killer (NK) cells bearing the chemokine receptor CXCR3. We investigated Mig as an immunotherapeutic agent in a syngeneic murine model of metastatic breast cancer. We transfected the highly malignant murine mammary tumor cell line 66.1 to stably express murine Mig cDNA. Immune-competent mice injected with Mig-expressing tumor cells developed smaller local tumors and fewer lung metastases, and they survived longer than mice injected with vector-control tumor cells. Mig-mediated inhibition of local tumor growth was lost in the absence of host T cells. Mig-transduced tumors had increased numbers of CD4+ T cells compared with vector-control tumors, consistent with the T-cell chemoattractant property of Mig, and many tumor-infiltrating host cells expressed CXCR3. NK cells had not been examined previously as a possible effector cell in Mig-based therapies. Our studies now show that NK cells are critical to the mechanism by which Mig limits metastasis. Inhibition of angiogenesis was not implicated as a mechanism of Mig-mediated therapy in this model. These studies support the hypothesis that by manipulating the Mig-CXCR3 gradient, it is possible to direct host immune effector cells to tumors, curtailing both local tumor growth and metastasis. These studies also implicate host NK cells as an additional effector cell critical for Mig-mediated control of metastasis.

[1]  Michael G. Johnson,et al.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. , 2006, Cancer research.

[2]  R. Strieter,et al.  Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2006, Cancer research.

[3]  M. Burdick,et al.  CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis1 , 2006, The Journal of Immunology.

[4]  J. Blay,et al.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.

[5]  P. Hensbergen,et al.  The CXCR3 Targeting Chemokine CXCL11 Has Potent Antitumor Activity In Vivo Involving Attraction of CD8+ T Lymphocytes But Not Inhibition of Angiogenesis , 2005, Journal of immunotherapy.

[6]  Xinrong Ma,et al.  Cyclooxygenase inhibitors modulate NK activities that control metastatic disease , 2005, Cancer Immunology, Immunotherapy.

[7]  B. Quesnel,et al.  NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. , 2005, Blood.

[8]  S. Horita,et al.  High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. , 2004, The Journal of urology.

[9]  M. Huang,et al.  EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-γ-Dependent Antitumor Responses in a Lung Cancer Model , 2003, The Journal of Immunology.

[10]  M. Huang,et al.  Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2003, Human gene therapy.

[11]  M. Tagawa,et al.  Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects. , 2003, Oncology reports.

[12]  M. Huang,et al.  SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10 , 2003, Molecular Cancer.

[13]  J. Xiang,et al.  Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors , 2002, Cancer Gene Therapy.

[14]  C. Tannenbaum,et al.  Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. , 2002, Cancer research.

[15]  J. Xiang,et al.  Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. , 2002, Cellular immunology.

[16]  A. Feldman,et al.  Retroviral gene transfer of interferon‐inducible protein 10 inhibits growth of human melanoma xenografts , 2002, International journal of cancer.

[17]  N. Giese,et al.  Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice , 2002, Cancer Gene Therapy.

[18]  Y. Ba,et al.  MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. , 2001, Cancer research.

[19]  R. Strieter,et al.  Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2001, Cancer research.

[20]  G. Gaedicke,et al.  IFN-γ-Inducible Protein-10 Is Essential for the Generation of a Protective Tumor-Specific CD8 T Cell Response Induced by Single-Chain IL-12 Gene Therapy1 , 2001, The Journal of Immunology.

[21]  R. Dorsey,et al.  Expression of the Chemokines IP-10 and Mig in IL-10 Transduced Tumors , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[22]  M. Hitt,et al.  Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity , 2001, Gene Therapy.

[23]  M. Burdick,et al.  Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo1 , 2000, The Journal of Immunology.

[24]  J. Murray,et al.  Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[25]  J. Prieto,et al.  Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 , 2000, The Journal of Immunology.

[26]  M. Iannettoni,et al.  The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. , 2000, Human gene therapy.

[27]  E. Bröcker,et al.  Strong expression of the lymphoattractant C‐X‐C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma , 1999, The Journal of pathology.

[28]  T. Olencki,et al.  Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma , 1999 .

[29]  A. Fulton,et al.  Interleukin‐10 gene transfer activates interferon‐γ and the interferon‐γ‐inducible genes Gbp‐1/Mag‐1 and Mig‐1 in mammary tumors , 1999 .

[30]  J. Teruya-Feldstein,et al.  Contribution of the CXC chemokines IP‐10 and Mig to the antitumor effects of IL‐12 , 1998, Journal of leukocyte biology.

[31]  R. Strieter,et al.  Tumor angiogenesis is regulated by CXC chemokines. , 1998, The Journal of laboratory and clinical medicine.

[32]  J. Finke,et al.  The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.

[33]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[34]  F. Balkwill,et al.  Multiple molecular and cellular changes associated with tumour stasis and regression during IL‐12 therapy of a murine breast cancer model , 1998, International journal of cancer.

[35]  J. Teruya-Feldstein,et al.  Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .

[36]  J. Farber Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.

[37]  L. Koniaris,et al.  Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Whyte,et al.  Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases , 1996, The Journal of experimental medicine.

[39]  Simon A. Jones,et al.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.

[40]  J. Finke,et al.  Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. , 1996, Journal of immunology.

[41]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[42]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[43]  D. Dexter,et al.  Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.

[44]  P. Sinha,et al.  Tumor-Associated Myeloid-Derived Suppressor Cells , 2007 .

[45]  E. Jaffee,et al.  Cancer Immunotherapy : Immune Suppression and Tumor Growth , 2007 .

[46]  F. Miller,et al.  From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. , 2004, Breast disease.

[47]  T. Olencki,et al.  Interferon-g and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma , 1999 .